SynthesisPloS one2026
Identifying regulatory driver motifs in non-small cell lung carcinoma via a systematic approach.
Synthesis in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer exhibits highest incidence among all cancer types worldwide and even after rigorous research and advanced treatment strategies, it constitutes a primary cause of cancer-related mortality. Non-small cell lung cancer is the predominant subtype, constituting the majority of lung cancer cases. Therefore, exploring novel biomarkers is crucial for betterment of diagnostic and therapeutic approaches.
methodsThe meta-analysis was performed using GEO datasets, to explore the differentially expressed genes (DEGs) and miRNAs (DEMs) in the non-small cell lung cancer (NSCLC) cases. We explored the ChEA database to extract the relevant transcription factors regulating the expression of our hub genes. Further, based on the highest degree of centrality, the feed-forward loop was identified with highest sub-network motif comprising of gene-TF-miRNA. We used pathway and GO term enrichment analysis to determine the importance of these DEGs in different biological processes.
resultsIn NSCLC, we found 950 differentially expressed miRNAs and 1761 genes were recognized exhibiting the significant change in expression (p < 0.05). Further, we investigated the role of sub-network motif in patient survival, hsa-miR-5010 was found to be significantly linked with patient outcome in Lung Adenocarcinoma (LUAD) (p = 0.033) and Lung Squamous Cell Carcinoma (LUSC) (p = 0.013) while SMAD4 (p < 0.001) and NRG1 (p < 0.001) expression exhibited prognostic significance in LUAD cohort only.
conclusionOur data indicated that NRG1-SMAD4-miR-5010-5p was the most prominent sub-network motif engaged in NSCLC patients based on the degree of centrality. In vitro mechanistic studies will provide better understanding on the role of NRG1-SMAD4-miR-5010-5p motif in NSCLC cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.